Browse the evidence

Tirzepatide and GLP-1 RA across all doses had significant increases in gastrointestinal adverse effects compared to placebo.

Clinicians should monitor gastrointestinal side effects in patients treated with tirzepatide and GLP-1 RA.

Current rates of WMT utilization among patients with obesity are low, increasing from 5.3% to 7.1%.

Efforts should be made to increase the utilization of WMT among patients with obesity.

Serum levels of brain-derived neurotrophic factor (BDNF) significantly increased in the TRF group.

Increased BDNF levels may indicate improved brain function related to eating behaviors in women undergoing TRF.

Cognitive restriction scores were higher in the TRF group compared to the control group.

Higher cognitive restriction scores in the TRF group suggest improved self-regulation in eating behaviors.

Treatment persistence was high, with 80% of patients completing 6 months of therapy.

High treatment persistence suggests that patients are likely to continue tirzepatide therapy.

Gastrointestinal adverse events were the most frequently reported but rarely led to treatment discontinuation.

Practitioners should monitor for gastrointestinal side effects but can expect them to be manageable.

Gastrointestinal adverse effects were the most commonly reported side effects of retatrutide.

Clinicians should monitor for gastrointestinal side effects in patients treated with retatrutide.

The most common adverse events in the retatrutide groups were gastrointestinal and were mostly mild to moderate in severity.

Practitioners should monitor for gastrointestinal side effects in patients treated with retatrutide.

About 14% caloric restriction for 2 years in healthy humans improved thymopoiesis.

Caloric restriction may enhance immune function in healthy individuals.

Caloric restriction-induced transcriptional reprogramming in adipose tissue implicated pathways regulating mitochondrial bioenergetics, anti-inflammatory responses, and longevity.

Caloric restriction may promote metabolic health through specific molecular pathways.

Reduction of PLA2G7 may mediate the immunometabolic effects of caloric restriction and could potentially lower inflammation and extend health span.

Targeting PLA2G7 may be a strategy to reduce inflammation and improve health span.

Use of GLP-1 receptor agonists (GLP-1 RAs) is associated with an increased risk of gallbladder or biliary diseases (RR, 1.37; 95% CI, 1.23-1.52).

Healthcare providers should be aware of the potential increased risk of gallbladder diseases when prescribing GLP-1 RAs.

GLP-1 RA use is associated with a higher risk of gallbladder or biliary diseases at higher doses (RR, 1.56; 95% CI, 1.36-1.78) compared to lower doses (RR, 0.99; 95% CI, 0.73-1.33).

Dosing strategies for GLP-1 RAs should consider the potential increased risk of gallbladder diseases.

One-year discontinuation was significantly higher for patients without type 2 diabetes (64.8%) compared with those with type 2 diabetes (46.5%).

Practitioners should be aware that patients without type 2 diabetes may struggle more with adherence to GLP-1 RA therapy.

There is a need for more accurate measures of muscle mass and function for diagnosing sarcopenia.

Practitioners should seek to utilize more accurate measurement tools for assessing sarcopenia.

There is a significant and growing public interest in Ozempic and related GLP-1 agonists.

Healthcare providers should be prepared for increased inquiries about these medications.

Ozempic users increased from 569 in 2019 to 7667 in 2020, with a count of 22,891 in 2022.

Practitioners should be aware of the rapid increase in Ozempic usage, indicating its growing acceptance and demand.

Global mean intake of processed meat was 17 g/day, with mean national intakes of at least one serving per day for processed meat in countries representing 6.9% of the global population.

Health professionals should consider the prevalence of processed meat consumption in their dietary recommendations.

Adverse events were more frequent with liraglutide, with 80% of participants experiencing gastrointestinal events compared to 57% with placebo.

Clinicians should monitor for gastrointestinal side effects when prescribing liraglutide.

Resmetirom achieved resolution of steatohepatitis without worsening of fibrosis in 26%-30% of participants compared to 10% for placebo.

Resmetirom may be an effective treatment option for patients with MASH and moderate to advanced liver fibrosis.

Resmetirom improved fibrosis without worsening of steatohepatitis in 24%-26% of participants compared to 14% for placebo.

Resmetirom may help improve liver fibrosis in patients with MASH without worsening their condition.

Significant gaps remain for achieving equity in nutrition security across the life span.

Efforts must be made to address gaps in nutrition security for all age groups.

The prevalences of type 2 diabetes and stroke mortality are higher in all Asian American subgroups compared with non-Hispanic White adults.

Health care professionals should prioritize screening for type 2 diabetes and stroke in Asian American populations.

Atherosclerotic cardiovascular disease risk is highest among South Asian and Filipino adults but lowest among Chinese, Japanese, and Korean adults.

Targeted interventions may be necessary for South Asian and Filipino populations to address higher cardiovascular risks.